Healthcare Industry News: Stereotactic
News Release - November 25, 2015
Elekta: Karolinska University Hospital to Purchase Elekta’s Leksell Gamma Knife IconNew System is Most Precise Stereotactic Radiosurgery System on the Market
STOCKHOLM--(Healthcare Sales & Marketing Network)--By acquiring Elekta’s (EKTA-B.ST) latest generation intracranial Stereotactic radiosurgery system, Leksell Gamma Knife® Icon™, Stockholm’s Karolinska University Hospital will be able to offer the benefits of precision cranial radiosurgery to more patients with a wider variety of tumor types and sizes.
The hospital was instrumental in the history of radiosurgery as Lars Leksell, Elekta’s founder, received his medical degree at Karolinska Institutet, then went on to develop the original Leksell Gamma Knife® system while serving as a professor of neurosurgery there.
Gamma Knife Icon is the sixth generation of the company’s Leksell Gamma Knife system, a technology that has been in use worldwide and continually evolving since the 1980s. With Stereotactic imaging, online Adaptive DoseControl™, ultra-precise dose delivery and the availability of frameless treatments, Icon is capable of treating virtually any target in the brain, regardless of type, location or volume.
Tomas Puusepp, Elekta’s President and CEO, says: “We are happy that Karolinska University Hospital has chosen the most advanced Leksell Gamma Knife radiosurgery system when they open the doors to their new hospital, New Karolinska Solna. We hope to continue working with Karolinska to provide them with the best solutions available as they strive to improve patient care.”
For more information on Leksell Gamma Knife Icon, visit www.careforthebrain.com
For further information, please contact: Gert van Santen, Group Vice President Corporate Communications, Elekta AB Tel: +31 653 561 242, e-mail: firstname.lastname@example.org Time zone: CET: Central European Time
Johan Andersson, Director, Investor Relations, Elekta AB Tel: +46 702 100 451, e-mail: email@example.com Time zone: CET: Central European Time The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on November 25, 2015.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.